Log In

 
Company : Business Wire 
Monday, October 4, 2004 3:05PM IST (9:35AM GMT)
 
( BW)(NV-ARTEC)(ATKJ)
ArTec, Inc., of Reno, Nevada, Announces the Olympic Winning Spirit of Tubercin in Saving the Life of a Greek Student with Acute Cancer
Nev., Reno, United States

ArTec, Inc., (Pink Sheets:ATKJ) A Pharmaceutical Company, announces the Olympic winning spirit of Tubercin in saving the life of a Greek student with acute cancer. On Aug. 28, 2004, The Maeil Shinmun,(www.imaeil.com) a South Korea newspaper carried an article about Dr. Tai Ho Chung, M.D. Ph.D. and Tubercin saving the life of a 17 year old Greek suffering from a rare form of fatal cancer in Athens where the Olympics was being held. Vasilios-Ioannis Manousakis was able to attend the Olympics and cheer his favorite teams during the Olympics.

V. I. Manousakis contracted intra-abdominal desmoplastic round cell tumor, which is a rare cancer effecting 200 patients all over the world and is a deadly disease and a type of pancreatic cancer. On a mission of mercy, the father of the patient contacted Dr. Tai Ho Chung, M.D. Ph.D., ArTec, Inc.'s Scientific Advisor and Principal Partner.

The father is professor Arkadios Manousakis, age 50, who is an eminent physicist at Athens National University. Since then this case has been the talk of the town culminating in a newspaper article on the front page in the South Korea newspaper The Maeil Shinmun, "Medicine with love from Daegu saved a Greek," Aug. 28, 2004 (www.imaeil.com).

Before treatment, the cancer had metastasized in the liver and spread in the peritoncal cavity. No one could predict his life expectancy. After successful Tubercin treatment, Dr. Tai Ho Chung relates, "The patient went to the stadium to support the teams and in an interview with the reporter, the patient mentioned he had recovered to 70% of his normal state."

Artec, Inc. desires to make Tubercin available to all the V. Manousakis of the world, now and later. The entire article, translated into English, will be available on ArTec, Inc.'s web site.

Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

 
 
 
Submit your press release
More News from Business Wire

18/06/2018 10:15AM

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

Following are the latest Corporate Social Responsibility news releases and story ideas available from Business Wire. These recaps, curated by Business Wire, provide reporters and bloggers around the globe instant access ...

01/06/2018 12:38PM

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

Following are the latest Corporate Social Responsibility news releases and story ideas available from Business Wire. These recaps, curated by Business Wire, provide reporters and bloggers around the globe instant access ...

25/05/2018 12:18PM

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

Following are the latest Corporate Social Responsibility news releases and story ideas available from Business Wire. These recaps, curated by Business Wire, provide reporters and bloggers around the globe instant access ...

Similar News

01/02/2018 3:48PM Image

Dr. Alok Roy, Chairman, Medica Hospitals Pvt Ltd, Views on Union Budget (2018-2019)

First time in many decades the Government in its Union Budget has shown serious commitment towards improvement in Healthcare.

No Image

08/11/2017 11:10AM

Progenity Announces Closing of $125 Million Financing for Prenatal-Women’s Health Genetics and Gastrointestinal/Inflammatory Bowel Disease Precision Medicine

Progenity Inc., a private biotechnology company, announced the completion of a privately placed $125 million Series B financing comprising equity and debt. The financing was led by a fund managed by an existing ...